Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 4

Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene

Authors Victor G Vogel

Published 5 December 2008 Volume 2008:3(4) Pages 601—609


Review by Single-blind

Peer reviewer comments 2

Victor G Vogel

The University of Pittsburgh Cancer Institute, Magee-Womens Hospital, Pittsburgh, PA, USA

Abstract: Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting. Raloxifene significantly improves serum lipids and serum markers of cardiovascular disease risk, but it has no significant effect on the risk of primary coronary events. A meta-analysis of randomized, double-blind, placebo-controlled trials of raloxifene for osteoporosis showed the odds of fracture risk were 0.60 (95% confidence interval [CI] = 0.49–0.74) for raloxifene 60 mg/day compared with placebo. During 8 years of follow-up in an osteoporosis trial, the raloxifene group had a 76% reduction in the incidence of invasive ER-positive breast cancer compared with the placebo group. In the STAR trial, the incidence of invasive breast cancer was 4.30 per 1000 women-years with raloxifene and 4.41 per 1000 with tamoxifen; RR = 1.02; 95% CI, 0.82–1.28. The effect of raloxifene on invasive breast cancer was, therefore, equivalent to that of tamoxifen with more favorable rates of adverse effects including uterine malignancy and clotting events. Millions of postmenopausal women could derive net benefit from raloxifene through reduced rates of fracture and invasive breast cancer.

Keywords: raloxifene, osteoporosis, breast cancer risk reduction

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Readers of this article also read:

Evidence for the long term cost effectiveness of home care reablement programs

Lewin GF, Alfonso HS, Alan JJ

Clinical Interventions in Aging 2013, 8:1273-1281

Published Date: 2 October 2013

Valuing the person’s story: Use of life story books in a continuing care setting

Teresa Wills, Mary Rose Day

Clinical Interventions in Aging 2008, 3:547-552

Published Date: 12 September 2008

Mild cognitive impairment: Conceptual, assessment, ethical, and social issues

Perla Werner, Amos D Korczyn

Clinical Interventions in Aging 2008, 3:413-420

Published Date: 12 September 2008

Zoster vaccine live for the prevention of shingles in the elderly patient

Jamie Zussman, Lorraine Young

Clinical Interventions in Aging 2008, 3:241-250

Published Date: 6 June 2008

Clinical challenges in the management of osteoporosis

Sheryl F Vondracek, Paul Minne, Michael T McDermott

Clinical Interventions in Aging 2008, 3:315-329

Published Date: 6 June 2008

Pharmacological treatment of neuropathic pain in older persons

Clair Haslam, Turo Nurmikko

Clinical Interventions in Aging 2008, 3:111-120

Published Date: 7 March 2008

Female pattern hair loss: Current treatment concepts

Quan Q Dinh, Rodney Sinclair

Clinical Interventions in Aging 2007, 2:189-199

Published Date: 15 July 2007

Nonpharmacological prevention of osteoporotic fractures

Cathy R Kessenich

Clinical Interventions in Aging 2007, 2:263-266

Published Date: 15 July 2007

BMI and low bone mass in an elderly male nursing home population

Miguel A Paniagua, Julie E Malphurs, Luis F Samos

Clinical Interventions in Aging 2006, 1:283-287

Published Date: 15 September 2006